| Date | Title | Description | Source |
| 19.01.2021 | Forbion invests USD 2.3M in seed financing of CoviCept Thera... | Naarden, The Netherlands, and Munich, Germany, January 19 2021 – Forbion, a leading European life sc... | forbion.co... |
| 10.01.2018 | Lummy Invests $1.5 Million in Argos Therapeutics | Argos Therapeutics Inc., biotechnology company headquartered in Durham, North Carolina, announced th... | archive.ci... |
| 10.01.2018 | Lummy Invests $1.5 Million in Argos Therapeutics | Argos Therapeutics Inc., biotechnology company headquartered in Durham, North Carolina, announced th... | citybizlis... |
| 29.06.2016 | The biotech IPO feast flags as investors lose their appeti... | There was a time after the 2008 crash that biotech IPOs were about as popular as snow in March. B... | endpts.com... |
| 11.03.2016 | Argos Therapeutics Announces Financing of up to $60 Million | Argos Therapeutics, Inc. (Nasdaq: ARGS) ("Argos"), an immuno-oncology company focused on t... | forbion.co... |
| 08.03.2016 | Argos Therapeutics Announces Financing of Up to $60 Million | DURHAM, N.C., March 07, 2016 (GLOBE NEWSWIRE) — Argos Therapeutics, Inc. (Nasdaq:ARGS) (“Argos”), an... | lumiravent... |
| 17.07.2015 | Argos Therapeutics Announces Completion of Patient Enrollmen... | Fully Personalized Immunotherapy is Being Evaluated in Combination With Standard Targeted Therapy fo... | tvm-lifesc... |
| 20.02.2014 | TVM Capital Life Science counts two successful biotech IPOs ... | Munich, Montreal, February 19, 2014 — Biotech IPOs continue to roll on and it is an explicit pleasur... | tvm-lifesc... |
| 21.11.2013 | Argos Therapeutics Inks Additional $17.5M of Series E |
DURHAM, NC, Biopharmaceutical company focused on the development and commercialization of fully pe... | vcnewsdail... |
| 20.11.2013 | Argos Therapeutics Announces Additional $17.5 Million of Ser... | Argos Therapeutics Inc., a biopharmaceutical company focused on the development and commercializatio... | forbion.co... |
| 20.11.2013 | Argos Therapeutics Raises $17.5M in Series E Financing | Argos Therapeutics Inc., a Durham, North Carolina-based biopharmaceutical company focused on the dev... | finsmes.co... |
| 30.08.2013 | Argos Therapeutics Secures $42.5 Million Financing, | Argos Therapeutics Inc., a biopharmaceutical company focused on the development and commercializatio... | forbion.co... |
| 28.08.2013 | Argos Therapeutics Secures $42.5M in Series E Financing | Argos Therapeutics Inc., a Durham, North Carolina-based biopharmaceutical company focused on the dev... | finsmes.co... |
| 28.08.2013 | Argos Therapeutics Secures $42.5 Million Financing, Funds Pi... | Argos Therapeutics Inc., a biopharmaceutical company focused on the development and commercializatio... | lumiravent... |
| 26.08.2013 | Argos Therapeutics Secures $42.5 Million Financing, Funds Pi... | Lead Investor Pharmstandard Commits $30 Million and Receives Russian Commercialization Rights
DURHA... | tvm-lifesc... |
| 26.08.2013 | Argos Therapeutics Secures $42.5M |
DURHAM, NC, Biopharmaceutical company focused on the development and commercialization of fully pe... | vcnewsdail... |
| 26.08.2013 | Argos Therapeutics Secures $42.5 Million Financing, Funds Pi... | Argos Therapeutics Inc., a biopharmaceutical company focused on the development and commercializatio... | forbion.co... |
| 15.01.2013 | Personalized immunotherapy could signal first combination tr... | CEO Jeff Abbey told MedCity News that more than 50 percent of patients in a phase 2 study for the th... | medcitynew... |
| 13.01.2013 | Argos Therapeutics Enrolls Initial Patients in Pivotal Phase... | Learn More-External Link
| lumiravent... |
| 08.06.2012 | Experimental lupus therapy from Argos in partnering talks af... | Argos had planned to support its drug development efforts pipeline with an initial public stock offe... | medcitynew... |
| 07.06.2012 | Argos Therapeutics Presents Positive Phase 1a Data for AGS-0... | Learn More-External Link | lumiravent... |
| 24.04.2012 | Argos Therapeutics Secures $25 million Series D Financing | Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patient... | lumiravent... |
| 24.04.2012 | Argos Therapeutics Secures $25 million Series D Financing to... | –Arcelis™ Immunotherapy AGS-003 Granted U.S. FDA Fast Track Designation for Treatment of mRCC– Durha... | tvm-lifesc... |
| 24.04.2012 | Argos raises $25M for kidney cancer immunotherapy phase 3 st... | Full phase 2 results of AGS-003 were reported in February. Those results showed that when used with ... | medcitynew... |
| 24.04.2012 | Argos Therapeutics Raises $25M in Series D Financing | Argos Therapeutics, a Durham, North Carolina-based biopharmaceutical company focused on the developm... | finsmes.co... |
| 24.04.2012 | Argos Therapeutics Secures $25 million Series D Financing | Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patient... | lumiravent... |
| 24.04.2012 | Argos Therapeutics Secures $25 million Series D Financing to... | - | forbion.co... |
| 07.03.2012 | No IPO for immunotherapy company Argos Therapeutics | But the public markets have remained cool to life science IPOs. Merrimack Pharmaceuticals, a a Cambr... | medcitynew... |
| 04.02.2012 | Argos Therapeutics Announces New Data Demonstrating Prolonge... | SOURCE: Argo Therapeutics | lumiravent... |
| 31.01.2012 | Argos Therapeutic Arcelis™ Immunotherapy AGS-003 in Combinat... | Learn More-External Link | lumiravent... |
| 29.07.2011 | Argos Therapeutics IPO would raise up to $86 million | Argos’ immunotherapy technology, called Arcelis, induces a patient’s own immune system to fight dise... | medcitynew... |
| 29.07.2011 | What Argos Therapeutics plans to do with $86M from an IPO | Proceeds from the stock offering will be used to finance trials that will test lead product candidat... | medcitynew... |
| 29.07.2011 | Argos Therapeutics Files Registration Statement for Proposed... | Learn More-External Link | lumiravent... |
| 05.07.2011 | Argos Therapeutics Presents New Phase 2 Data Showing its Arc... | Learn More-External Link | lumiravent... |
| 13.05.2011 | Immunotherapy technology from Argos seeks partner for kidney... | Immunotherapy induces a patient’s own immune system to fight disease. Argo’s technology, called Arce... | medcitynew... |
| 04.05.2011 | Argos Therapeutics´ Immunotherapy Platform Based on Recombin... | Learn More-External Link | lumiravent... |
| 29.03.2011 | North Carolina vaccine developer Chimerix names Trost new CF... | Promoted
This Patient Experience Checklist Is Your Key To Success in 2021
As healthcare systems st... | medcitynew... |
| 01.10.2010 | Argos Therapeutics´ Arcelis™ Immunotherapy for Renal Cell Ca... | Learn More-External Link | lumiravent... |
| 24.11.2008 | Argos Therapeutics Completes $35.2 Million Series C Financin... | - | forbion.co... |
| 21.11.2008 | Argos Therapeutics Completes $35.2 Million Series C Financin... | Learn More-External Link | lumiravent... |
| 23.04.2008 | Argos Therapeutics Secures $35.2 Million Series C Financing |
Argos Therapeutics Secures $35.2 Million Series C Financing
—Funding to Advance Arcelis™ Person... | lumiravent... |
| 23.04.2008 | Argos Therapeutics Secures $35.2 Million Series C Financing | - | forbion.co... |
| 20.04.2007 | Argos Therapeutics Raises $5.0 Million in Debt Financing | Learn More-External Link | lumiravent... |
| - | Argos raises $25M for kidney cancer immunotherapy phase 3 st... | Immunotherapy company Argos Therapeutics, which last month withdrew plans for a $65 million initial ... | medcitynew... |
| - | Argos Therapeutics IPO would raise up to $86 million | Immunotherapy company Argos Therapeutics has filed for an initial public stock offering that could r... | medcitynew... |
| - | Immunotherapy technology from Argos seeks partner for kidney... | Immunotherapy company Argos Therapeutics has developed a new technology that could set it apart from... | medcitynew... |
| - | What Argos Therapeutics plans to do with $86M from an IPO | Immunotherapy company Argos Therapeutics plans to start enrolling patients in a phase 3 kidney cance... | medcitynew... |
| - | No IPO for immunotherapy company Argos Therapeutics | Immunotherapy company Argos Therapeutics has pulled back on its plans for an initial public offering... | medcitynew... |
| - | North Carolina vaccine developer Chimerix names Trost new CF... | Vaccine developer Chimerix has added life sciences industry veteran Timothy Trost to its management ... | medcitynew... |
| - | Experimental lupus therapy from Argos in partnering talks af... | The experimental lupus treatment being developed by Argos Therapeutics is showing promise in early s... | medcitynew... |
| - | Personalized immunotherapy could signal first combination tr... | It’s been a few months since Dendreon got slammed for providing inconsistent data analysis to U.S. r... | medcitynew... |
